Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Net Income towards Common Stockholders (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Net Income towards Common Stockholders data on record, last reported at $45.0 million in Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 259.21% year-over-year to $45.0 million; the TTM value through Dec 2025 reached $96.7 million, up 23.8%, while the annual FY2025 figure was $108.6 million, 15.75% up from the prior year.
  • Net Income towards Common Stockholders reached $45.0 million in Q4 2025 per COLL's latest filing, up from $31.5 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $74.0 million in Q2 2021 and bottomed at -$25.0 million in Q4 2021.
  • Average Net Income towards Common Stockholders over 5 years is $14.4 million, with a median of $12.8 million recorded in 2023.
  • Peak YoY movement for Net Income towards Common Stockholders: plummeted 459.79% in 2021, then skyrocketed 4415.1% in 2023.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$25.0 million in 2021, then skyrocketed by 71.24% to -$7.2 million in 2022, then soared by 748.84% to $46.7 million in 2023, then crashed by 73.16% to $12.5 million in 2024, then skyrocketed by 259.21% to $45.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income towards Common Stockholders were $45.0 million in Q4 2025, $31.5 million in Q3 2025, and $17.0 million in Q2 2025.